Efficacy of TTMPB in Adult Cardiac Surgery

Inclusion Criteria: Direct informed consent as documented by signature Major adult (≥ 18 years old) with body weight ≥ 50 kg. For the record, fifty kilograms is the minimal weight to ensure that participants remain safely away from maximal doses of LA (3 mg/kg) Planned and primary cardiac surgery via a sternotomy approach Planned for ultra-fast-track procedure (i.e. postoperative extubation time of maximum two hours) Exclusion Criteria: Participation in another study with investigational drug within the 30 days preceding and during the present study Refusal and/or inability to understand or sign the informed consent Emergent cardiac surgery Previous cardiac surgery Known hypersensitivity or true allergy to bupivacaine and other amide-class LA Chronic pain history Substance abuse history Inability to follow the procedures of the study (e.g. due to language problems, psychological / psychiatric disorders, dementia) Clinically significant concomitant diseases: severe cardiac dysfunction (i.e. LVEF ≤ 35%); severe chronic obstructive pulmonary disease (i.e. FEV < 50%); severe hepatic disease. Severe obesity (BMI > 35kg/m2)